Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Graft vs Host Disease 1Cholangiocarcinoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 5ruxolitinib 3Sirolimus 3Mycophenolic Acid 3fludarabine 2asciminib 2Filgrastim 2Cyclophosphamide 2posaconazole 1pegfilgrastim 1montelukast 1axatilimab 1Whole-Body Irradiation 1Voriconazole 1Tomography, X-Ray Computed 1Specimen Handling 1Saline Solution 1Rituximab 1Respiratory Function Tests 1Proto-Oncogene Proteins c-raf 1Prednisone 1Photopheresis 1Pentostatin 1Panobinostat 1Methotrexate 1Mesna 1Infliximab 1Imatinib Mesylate 1Everolimus 1Erythropoietin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bronchiolitis Obliterans Syndrome × axatilimab × 1 year × Clear all
NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡